NDA 214032 · Telix
Illuccix
Gallium Ga-68 Gozetotide · Intravenous
Last checked: Nov 19, 2026Latest source record: Dec 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Dec 17, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
134
22 Phase 3, 24 recruiting
FAERS reports
194
17 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 25, 2026.
ILLUCCIX, after radiolabeling with Ga 68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level For selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products ILLUCCIX, after radiolabeling with Ga 68, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level For selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 15, 2023 Supplement 1 · Efficacy LabelLetter
- Dec 17, 2021 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination LetterReview
1 products under this application
- ILLUCCIX · GALLIUM GA-68 GOZETOTIDE N/A · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gallium Ga-68 Gozetotide" as an intervention, any sponsor and status, largest first.
University of MichiganAcademic, hospital or other
NCT03396874 · 1,435 participants · Start Feb 9, 2018 · Primary completion Aug 9, 2022
Drug: 68Ga-PSMA · For: Prostate Cancer; Prostate Adenocarcinoma; Prostate Cancer Metastatic and 1 more
Sites: Ann Arbor, Michigan
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSAcademic, hospital or other
NCT02920229 · 1,230 participants · Start Nov 2015 · Primary completion Oct 9, 2020
Drug: 68Ga- PSMA · For: 68Ga-PSMA HBED-PET/CT; Prostate Cancer
Sites: Meldola, Italy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSAcademic, hospital or other
NCT03453528 · 1,225 participants · Start Jul 4, 2017 · Primary completion Dec 4, 2024
Drug: 68Ga-PSMA · For: Prostate-specific Membrane Antigen; mCRPC or Advanced/Metastatic Solid Tumors
Sites: Meldola, Italy
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04720157 · 1,144 participants · Start Jun 9, 2021 · Primary completion Jan 13, 2025
Drug: 177Lu-PSMA-617; 68Ga-PSMA-11 and 2 more · For: Prostatic Neoplasms
Sites: Scottsdale, Arizona; La Jolla, California; Los Angeles, California · 164 sites in all
- 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate CancerCompleted
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
NCT04050215 · 937 participants · Start Apr 2, 2018 · Primary completion Sep 27, 2021
Drug: Gallium Ga 68-labeled PSMA-11 · For: Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma and 6 more
Sites: Los Angeles, California
First Affiliated Hospital of Fujian Medical UniversityAcademic, hospital or other
NCT04831541 · 600 participants (planned) · Start Oct 10, 2020 · Primary completion Dec 30, 2024
Drug: 68Ga-PSMA-11 · For: Prostate Cancer; Positron-Emission Tomography
Sites: Fuzhou, China
- 68Ga-PSMA PET/CT in Prostate CancerPivotal-lookingCompleted
Sir Mortimer B. Davis - Jewish General HospitalAcademic, hospital or other
NCT03001869 · 540 participants · Start Jul 1, 2017 · Primary completion Jul 1, 2023
Drug: 68Ga-HBED-CC-PSMA PET/CT · For: Prostate Cancer
Sites: Montreal, Canada
- 68Ga-PSMA PET/CT in Prostate CancerPivotal-lookingSuspended
University of SaskatchewanAcademic, hospital or other
NCT04684628 · 500 participants (planned) · Start Dec 9, 2020 · Primary completion Jan 2025
Drug: 68Ga-PSMA PET/CT · For: Prostate Cancer
Sites: Saskatoon, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site pain128
- burning sensation9
- injection site discomfort8
- positron emission tomogram abnormal7
- loss of consciousness5
- syncope5
- chest pain4
- drug ineffective4
- product preparation error4
- seizure4
- diarrhoea3
- injection site haemorrhage3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 27 |
| 2023 | 58 |
| 2024 | 53 |
| 2025 | 44 |
| 2026 | 12 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Telix
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.